Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Current Assets data on record, last reported at $338.7 million in Q1 2026.

  • On a quarterly basis, Current Assets rose 45.63% to $338.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $338.7 million, a 45.63% increase, with the full-year FY2025 number at $357.5 million, up 43.04% from a year prior.
  • Current Assets reached $338.7 million in Q1 2026 per FULC's latest filing, down from $357.5 million in the prior quarter.
  • Over the last five years, Current Assets for FULC hit a ceiling of $357.5 million in Q4 2025 and a floor of $174.2 million in Q2 2022.
  • A 5-year average of $251.2 million and a median of $242.2 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 62.38% in 2023, then fell 28.03% in 2024.
  • Tracing FULC's Current Assets over 5 years: stood at $207.5 million in 2022, then increased by 16.71% to $242.2 million in 2023, then increased by 3.19% to $249.9 million in 2024, then skyrocketed by 43.04% to $357.5 million in 2025, then dropped by 5.26% to $338.7 million in 2026.
  • Business Quant data shows Current Assets for FULC at $338.7 million in Q1 2026, $357.5 million in Q4 2025, and $205.9 million in Q3 2025.